Severe tumor lysis syndrome during the induction therapy for the treatment of blastic plasmacytoid dendritic cell neoplasm arising from myelodysplastic/myeloproliferative neoplasms

BPDCN shows clinically heterogeneous characteristics. And as other hematological malignancies, symptoms of BPDCN suggesting a high tumor burden, such as high white blood cell count or splenomegaly, should be carefully considered to prevent TLS.

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Case Rep
Egile Nagusiak: Sagou, Ken, Ito, Makoto, Kawamura, Yuma, Ukai, Shun, Goto, Miyo, Fukushima, Nobuaki, Ozeki, Kazutaka, Fukuyama, Ryuichi, Kohno, Akio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Case Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869312/
https://ncbi.nlm.nih.gov/pubmed/33598264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3690
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak